Search research articles
Contact Us
Filters
Showing results (801-810 of 856) with videos related to
Page
of 86
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease
|
April 10, 2018
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial
Naimish R Patel, Danen M Cunoosamy, Malin Fagerås, et al.
BMC Medicine
|
February 3, 2025
Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy
Erin L Fee, Haruo Usuda, Sean W D Carter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data
C Jones, P Dutey-Magni, L R Murphy, et al.
Contemporary Clinical Trials
|
March 8, 2021
Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression trees
Mary Waterhouse, Catherine Baxter, Briony Duarte Romero, et al.
Plos One
|
June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
Radiology
|
June 6, 2018
Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology
Ross A Little, Yann Jamin, Jessica K R Boult, et al.
NEJM Evidence
|
February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Noel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
European Urology
|
October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JCO Precision Oncology
|
January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Clare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 16, 2023
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
D C Gilbert, M Nankivell, H Rush, et al.
Page
of 86
Search research articles
Search
Showing results (801-810 of 856) with videos related to
Sort By:
Page
of 86
International Journal of Chronic Obstructive Pulmonary Disease
|
April 10, 2018
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial
Naimish R Patel, Danen M Cunoosamy, Malin Fagerås, et al.
BMC Medicine
|
February 3, 2025
Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy
Erin L Fee, Haruo Usuda, Sean W D Carter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2025
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data
C Jones, P Dutey-Magni, L R Murphy, et al.
Contemporary Clinical Trials
|
March 8, 2021
Predicting deseasonalised serum 25 hydroxy vitamin D concentrations in the D-Health Trial: An analysis using boosted regression trees
Mary Waterhouse, Catherine Baxter, Briony Duarte Romero, et al.
Plos One
|
June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
Radiology
|
June 6, 2018
Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology
Ross A Little, Yann Jamin, Jessica K R Boult, et al.
NEJM Evidence
|
February 6, 2024
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Noel W Clarke, Andrew J Armstrong, Antoine Thiery-Vuillemin, et al.
European Urology
|
October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JCO Precision Oncology
|
January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Clare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
November 16, 2023
A Repurposing Programme Evaluating Transdermal Oestradiol Patches for the Treatment of Prostate Cancer Within the PATCH and STAMPEDE Trials: Current Results and Adapting Trial Design
D C Gilbert, M Nankivell, H Rush, et al.
Page
of 86